Full Press Release Details
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will participate in two upcoming investor conferences. Details are as follows:
| BIO CEO & Investor Conference | ||
| Date: | Monday, February 12, 2018 | |
| Forum: | Presentation | |
| Time: | 1:30 p.m. ET | |
| Location: | New York | |
| SunTrust Robinson Humphrey 4 th Annual Orphan Drug Day | ||
| Date: | Tuesday, February 13, 2018 | |
| Forum: | 1x1 Meetings | |
| Location: | New York |
A live webcast of the presentation will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.